Thomas Zindrick Sells 34,463 Shares of Genelux (NASDAQ:GNLX) Stock

Genelux Corporation (NASDAQ:GNLX) CEO Thomas Zindrick sold 34,463 shares of the firm’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $2.67, for a total value of $92,016.21. Following the sale, the chief executive officer directly owned 1,226,427 shares of the company’s stock, valued at $3,274,560.09. The trade was a 2.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Thomas Zindrick also recently made the following trade(s):

• On Tuesday, August 4th, Thomas Zindrick sold 3,023 shares of Genelux stock. The shares were sold at an average price of $2.95, for a total transaction of $8,917.85.

Genelux Price Performance

Shares of GNLX stock opened at $2.52 on Friday. The firm has a market cap of $114.00 million, a PE ratio of -2.93 and a beta of 0.57. The company has a 50-day moving average of $2.82 and a two-hundred day moving average of $2.78. Genelux Corporation has a 1-year low of $2.29 and a 1-year high of $8.53.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Sell-side analysts anticipate that Genelux Corporation will post -0.81 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on GNLX shares. Wall Street Zen raised Genelux from a “strong sell” rating to a “sell” rating in a research report on Sunday, August 23rd. Benchmark restated a “speculative buy” rating on shares of Genelux in a research report on Tuesday, August 18th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Genelux has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in GNLX. BlackRock Inc. purchased a new stake in shares of Genelux in the 2nd quarter valued at approximately $1,323,000. Geode Capital Management LLC raised its stake in Genelux by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 381,407 shares of the company’s stock valued at $1,664,000 after buying an additional 27,567 shares in the last quarter. Bank of America Corp DE purchased a new stake in Genelux during the 2nd quarter worth about $990,000. Flputnam Investment Management Co. purchased a new stake in Genelux during the 2nd quarter worth about $697,000. Finally, Global Retirement Partners LLC acquired a new position in shares of Genelux during the 2nd quarter worth about $686,000. Institutional investors and hedge funds own 37.33% of the company’s stock.

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.